Pacira Pharmaceuticals, Inc. (PCRX)

$19.98

-0.23

(-1.14%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $19.63
    $20.20
    $19.98
    downward going graph

    1.75%

    Downside

    Day's Volatility :2.82%

    Upside

    1.09%

    downward going graph
  • $19.34
    $40.16
    $19.98
    downward going graph

    3.2%

    Downside

    52 Weeks Volatility :51.84%

    Upside

    50.25%

    downward going graph

Returns

PeriodPacira Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-24.62%
5.3%
0.0%
6 Months
-37.62%
6.3%
0.0%
1 Year
-45.16%
9.2%
0.0%
3 Years
-65.57%
13.1%
-19.9%

Highlights

Market Capitalization
901.6M
Book Value
$19.18
Earnings Per Share (EPS)
1.51
PE Ratio
12.83
PEG Ratio
-3.83
Wall Street Target Price
44.4
Profit Margin
10.34%
Operating Margin TTM
9.05%
Return On Assets TTM
3.76%
Return On Equity TTM
8.49%
Revenue TTM
681.8M
Revenue Per Share TTM
14.71
Quarterly Revenue Growth YOY
4.2%
Gross Profit TTM
393.2M
EBITDA
167.8M
Diluted Eps TTM
1.51
Quarterly Earnings Growth YOY
0.29
EPS Estimate Current Year
2.65
EPS Estimate Next Year
3.63
EPS Estimate Current Quarter
0.62
EPS Estimate Next Quarter
0.69

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Pacira Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 122.22%

Current $19.98
Target $44.40

Company Financials

FY18Y/Y Change
Revenue
337.3M
↑ 17.67%
Net Income
-471.0K
↓ 98.89%
Net Profit Margin
-0.14%
↑ 14.73%
FY19Y/Y Change
Revenue
421.0M
↑ 24.83%
Net Income
-11.0M
↑ 2238.85%
Net Profit Margin
-2.62%
↓ 2.48%
FY20Y/Y Change
Revenue
420.8M
↓ 0.05%
Net Income
145.5M
↓ 1421.01%
Net Profit Margin
34.58%
↑ 37.2%
FY21Y/Y Change
Revenue
541.5M
↑ 28.68%
Net Income
42.0M
↓ 71.15%
Net Profit Margin
7.75%
↓ 26.83%
FY22Y/Y Change
Revenue
666.8M
↑ 23.14%
Net Income
15.9M
↓ 62.1%
Net Profit Margin
2.39%
↓ 5.36%
FY23Y/Y Change
Revenue
675.0M
↑ 1.22%
Net Income
42.0M
↑ 163.72%
Net Profit Margin
6.22%
↑ 3.83%
Q4 FY22Q/Q Change
Revenue
172.0M
↑ 2.68%
Net Income
-10.1M
↑ 1357.72%
Net Profit Margin
-5.87%
↓ 5.46%
Q1 FY23Q/Q Change
Revenue
160.3M
↓ 6.75%
Net Income
-19.5M
↑ 93.39%
Net Profit Margin
-12.18%
↓ 6.31%
Q2 FY23Q/Q Change
Revenue
169.5M
↑ 5.69%
Net Income
25.8M
↓ 231.87%
Net Profit Margin
15.2%
↑ 27.38%
Q3 FY23Q/Q Change
Revenue
163.9M
↓ 3.27%
Net Income
10.9M
↓ 57.85%
Net Profit Margin
6.62%
↓ 8.58%
Q4 FY23Q/Q Change
Revenue
181.2M
↑ 10.56%
Net Income
24.9M
↑ 129.05%
Net Profit Margin
13.72%
↑ 7.1%
Q1 FY24Q/Q Change
Revenue
167.1M
↓ 7.79%
Net Income
9.0M
↓ 63.9%
Net Profit Margin
5.37%
↓ 8.35%
FY18Y/Y Change
Total Assets
689.4M
↑ 9.7%
Total Liabilities
368.1M
↑ 5.51%
FY19Y/Y Change
Total Assets
831.1M
↑ 20.56%
Total Liabilities
476.1M
↑ 29.34%
FY20Y/Y Change
Total Assets
1.3B
↑ 53.36%
Total Liabilities
654.8M
↑ 37.53%
FY21Y/Y Change
Total Assets
2.1B
↑ 62.83%
Total Liabilities
1.3B
↑ 105.39%
FY22Y/Y Change
Total Assets
1.7B
↓ 18.99%
Total Liabilities
906.2M
↓ 32.62%
FY23Y/Y Change
Total Assets
1.6B
↓ 6.35%
Total Liabilities
704.3M
↓ 22.28%
Q4 FY22Q/Q Change
Total Assets
1.7B
↓ 3.07%
Total Liabilities
906.2M
↓ 6.02%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 9.39%
Total Liabilities
755.4M
↓ 16.64%
Q2 FY23Q/Q Change
Total Assets
1.5B
↑ 1.24%
Total Liabilities
734.4M
↓ 2.78%
Q3 FY23Q/Q Change
Total Assets
1.5B
↓ 0.51%
Total Liabilities
702.9M
↓ 4.29%
Q4 FY23Q/Q Change
Total Assets
1.6B
↑ 2.6%
Total Liabilities
704.3M
↑ 0.19%
Q1 FY24Q/Q Change
Total Assets
1.6B
↑ 0.57%
Total Liabilities
691.2M
↓ 1.86%
FY18Y/Y Change
Operating Cash Flow
48.9M
↑ 174.78%
Investing Cash Flow
20.6M
↓ 109.2%
Financing Cash Flow
9.0M
↓ 96.01%
FY19Y/Y Change
Operating Cash Flow
70.5M
↑ 44.3%
Investing Cash Flow
-128.5M
↓ 724.46%
Financing Cash Flow
3.7M
↓ 59.01%
FY20Y/Y Change
Operating Cash Flow
77.0M
↑ 9.23%
Investing Cash Flow
-277.6M
↑ 116.06%
Financing Cash Flow
222.3M
↑ 5957.33%
FY21Y/Y Change
Operating Cash Flow
125.7M
↑ 63.2%
Investing Cash Flow
-20.8M
↓ 92.51%
Financing Cash Flow
380.7M
↑ 71.25%
FY22Y/Y Change
Operating Cash Flow
145.3M
↑ 15.56%
Investing Cash Flow
-225.2M
↑ 983.14%
Financing Cash Flow
-401.5M
↓ 205.47%
Q4 FY22Q/Q Change
Operating Cash Flow
42.0M
↓ 1.45%
Investing Cash Flow
11.2M
↓ 123.55%
Financing Cash Flow
-58.5M
↑ 652.55%
Q1 FY23Q/Q Change
Operating Cash Flow
19.1M
↓ 54.5%
Investing Cash Flow
66.2M
↑ 491.5%
Financing Cash Flow
-153.9M
↑ 163.04%
Q2 FY23Q/Q Change
Operating Cash Flow
43.5M
↑ 127.41%
Investing Cash Flow
7.3M
↓ 88.93%
Financing Cash Flow
440.0K
↓ 100.29%

Technicals Summary

Sell

Neutral

Buy

Pacira Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
-30.43%
-37.62%
-45.16%
-65.57%
-49.47%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.73%
3.47%
45.25%
47.46%
69.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.24%
7.6%
2.41%
20.38%
20.38%
Zoetis Inc.
Zoetis Inc.
5.19%
-3.9%
-2.6%
-11.21%
55.91%
Viatris Inc.
Viatris Inc.
11.46%
-0.85%
9.89%
-16.16%
-28.58%
Catalent, Inc.
Catalent, Inc.
3.12%
18.35%
21.46%
-49.91%
6.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
12.83
12.83
-3.83
2.65
0.08
0.04
NA
19.18
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.34
34.34
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Buy
$901.6M
-49.47%
12.83
10.34%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
69.5%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.38%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.5B
55.91%
34.34
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-28.58%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
6.12%
211.02
-28.44%

Insights on Pacira Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 181.24M → 167.11M (in $), with an average decrease of 7.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 24.87M → 8.97M (in $), with an average decrease of 63.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 47.1% return, outperforming this stock by 92.6%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 47.5% return, outperforming this stock by 113.1%

Institutional Holdings

  • BlackRock Inc

    16.98%
  • Vanguard Group Inc

    10.99%
  • Frontier Capital Management CO Inc

    4.11%
  • State Street Corporation

    4.09%
  • Renaissance Technologies Corp

    4.04%
  • Dimensional Fund Advisors, Inc.

    3.50%

Company Information

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

Organization
Pacira Pharmaceuticals, Inc.
Employees
711
CEO
Mr. Charles A. Reinhart III, CPA, M.B.A.
Industry
Health Technology

FAQs